Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 5/20 | 0.42 |
| ▸ | BRAF | P15056 | 4/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034820 | 0.82 | JAK3 (0.46) | RXFP1KITBRAFTRPV1CYP3A4 | |
| SCHEMBL4034696 | 0.81 | JAK3 (0.47) | RXFP1KITBRAFTRPV1JAK3 | |
| SCHEMBL6542886 | 0.81 | JAK3 (0.51) | KITBRAFTRPV1JAK3IRAK4 | |
| SCHEMBL4032722 | 0.80 | KIT (0.50) | KITBRAF | |
| SCHEMBL4042743 | 0.80 | KIT (0.53) | KITBRAF | |
| SCHEMBL4034704 | 0.79 | JAK3 (0.46) | RXFP1KITBRAFTRPV1JAK3 | |
| SCHEMBL4042030 | 0.79 | JAK3 (0.47) | KITBRAFJAK3IRAK4FLT1 | |
| SCHEMBL4042753 | 0.78 | KIT (0.49) | KITBRAF | |
| SCHEMBL5900863 | 0.76 | RXFP1 (0.53) | RXFP1KITBRAFABL1EGFR | |
| SCHEMBL14483974 | 0.76 | ABCG2 (0.56) | CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | SCHERING AG (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | KDR, FLT1, FLT4 | RXFP1 40/4885KIT 23/4885BRAF 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.